Tyler Hong

VoxCell BioInnovation is a Canadian biotechnology company redefining drug development with high-resolution, vascularized 3D tissue models. By replicating the complex environment of human tissues, VoxCell empowers pharmaceutical and research institutions to study drug behavior with unprecedented physiological relevance. VoxCell stands at the forefront of a global shift toward reducing animal models in drug development. As regulators and industry leaders embrace New Approach Methodologies (NAMs), VoxCell’s technology delivers the complexity and predictive power needed to evaluate drug response and efficacy, reducing reliance on animals while accelerating the development of more effective therapies. With vascular complexity at the core of its innovation, VoxCell delivers human-like models that accelerate therapeutic discovery and bridge the gap between preclinical and clinical phases. Committed to innovation and excellence, VoxCell continues to expand its impact on a global scale.